Floatz logo

Edicotinib

Testosterone Greater Than 150 ng/dL

M.D. Anderson Cancer CenterSmall moleculePhase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Testosterone Greater Than 150 ng/dL cohort.

Asset / SponsorPhaseRating
Osilodrostat
Johns Hopkins University
Phase 4BBB
Anakinra
University Hospital, Basel, Switzerland
Phase 3BB
Metyrapone
Mayo Clinic
Phase 2CCC
DARATUMUMAB
M.D. Anderson Cancer Center
Phase 1CC
Semaglutide
University of Texas Southwestern Medical Center
N/AD
Solu-Cortef
University of Minnesota
Phase 1NR

Same molecule, other indications

Edicotinib is also rated in:

acute myeloid leukemiaDormant
CC
Indicative ·
43 / 100
View asset →
prostate cancerDormant
C
Indicative ·
39 / 100
View asset →
Relapsed or Refractory Hodgkin LymphomaDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →